Product Development

Research & Development

PlateletBio’s R&D pipeline focuses on developing novel and differentiated allogeneic cell products. The most advanced programs are immune thrombocytopenia (ITP) and impaired hemostatic conditions where the need for highly effective therapies is still largely unmet. The company’s expanding pipeline of engineered platelet-like cells (ePLCs) includes indications for autoimmune diseases, oncology, hematology and inflammation.

Pipeline

Program

Approach

Stage of Development

Discovery

Lead Optimization

IND Enabling

ITP

PLC expressing GPIIb/IIIa to bind and clear disease-specific autoantibodies

2021

Hemostasis*

PLC with hemostatic activity for treatment of thrombocytopenia

2021

Hepatic Cancer

ePLC co-expressing IL-12 & PD-1 for elimination of liver tumors

2022

Liver Fibrosis

ePLC expressing HGF for treatment of liver fibrosis

2022-2023

*Funded by BARDA

Manufacturing

Our proprietary biomimetic bioreactor produces platelet-like cells (PLCs) at scale. Under cGMP conditions, multiplexed bioreactors are easily stacked to produce large quantities of PLCs for clinical use. The same manufacturing platform is used for PlateletBio’s entire pipeline of products and is designed to easily scale to the specific requirements of each therapy.

PlateletBio has a well-established in-house cGMP manufacturing capability that provides quality oversight from materials acceptance through to product release.

Tower Station - View 2
Tower Station - View 1
City Station - View 1
City Station - View 2
Single Device - Dimetric
4-Layer Tower - Dimetric
40-Layer Tower - Dimetric
8 x 40 City - Dimetric
Single Device - Trimetric
4-Layer Tower - Trimetric
40-Layer Tower - Trimetric
8 x 40 City - Trimetric